Back to List View Graph View

Dolutegravir

Dolutegravir is an antiretroviral drug in the integrase strand transfer inhibitor class and is used in the treatment of HIV.

Where the papers sit

11 papers from the last 6 months study dolutegravir directly · updated from PubMed 10 Nov 2026

Those 11 are all about one subject.

  • HIV Treatment and Outcomes

    HIV treatment research is assessing dolutegravir-based regimens across adults and children, including first-line therapy, switching, and delivery strategies. Recurring concerns are low-level viremia, virological failure, resistance risk, and plasma or cerebrospinal-fluid exposure. Metabolic effects, HBV history, pediatric dosing, and access across regions broaden the clinical focus. The work shares a treatment-outcomes subject but does not establish one dominant therapeutic direction.

    11 papers

NEW DIRECTION

Dolutegravir is repositioned as a transdermal pediatric delivery component

The nanoemulsion-based transdermal delivery study of rilpivirine and dolutegravir for pediatric HIV treatment 42425238Jul moves dolutegravir beyond the oral antiretroviral regimens, pharmacokinetic studies, and clinical outcome assessments used by the other papers. Whereas those studies treat dolutegravir as an orally administered component of antiretroviral therapy, this study develops an optimized nanoemulsion to deliver dolutegravir and rilpivirine through the skin, aiming to address pediatric adherence, dosing complexity, and unpalatable taste. The resulting role is not merely a new clinical application of the established regimen but a new route and formulation for administering dolutegravir.

dolutegravir chemical structure

Papers

The 11 papers from the last 6 months that study dolutegravir directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

HIV Treatment and Outcomes (11)
  1. Burden and determinants of hyperglycaemia and dyslipidaemia in Zimbabwean adults living with HIV on dolutegravir-based first-line antiretroviral therapy: A cross-sectional study. PloS one · 7 Oct 2026 PMID 42842595
  2. Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV. CPT: pharmacometrics & systems pharmacology · 30 Sept 2026 PMID 42811541
  3. Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial. The lancet. HIV · 7 Sept 2026 PMID 42705257
  4. Plasma dolutegravir exposure testing to identify people with HIV at highest risk for dolutegravir resistance (ITREMA-2): a two-centre, prospective implementation study in South Africa. The lancet. HIV · 2 Sept 2026 PMID 42685737
  5. Pathways of onward HIV disclosure in relationships among young people living with vertically acquired HIV receiving antiretroviral therapy: A qualitative analysis from the BREATHER Plus trial, South Africa. Global public health · 20 Aug 2026 PMID 42623024
  6. ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir/lamivudine. Sexual health · 19 Aug 2026 PMID 42618052
  7. Low-Level Viremia and Spatial Heterogeneity Among Individuals on Dolutegravir-Based Antiretroviral Therapy in Botswana: A Nationwide Study (2016-2022). The Journal of infectious diseases · 17 Aug 2026 PMID 42605207
  8. Risk of Virological Failure After Switch to a Tenofovir-Sparing Dual Therapy in Virologically Suppressed People With HIV and Past HBV Infection. Journal of medical virology · 21 Jul 2026 PMID 42479941
  9. Nanoemulsion-based transdermal delivery of rilpivirine and dolutegravir for pediatric HIV treatment. International journal of pharmaceutics · 9 Jul 2026 PMID 42425238
  10. Comparative metabolic safety of efavirenz-, dolutegravir-, and bictegravir-based antiretroviral regimens in HIV-infected adults: Evidence for weight-dependent lipid deterioration. Journal of infection and public health · 25 Jun 2026 PMID 42349058
  11. Use of Integrase Strand Transfer Inhibitors Among Children Living With HIV in Latin America and the Caribbean. The Pediatric infectious disease journal · 22 May 2026 PMID 42168824

By study type

Clinical trials (3)
  1. Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial. The lancet. HIV · 7 Sept 2026 PMID 42705257
  2. Pathways of onward HIV disclosure in relationships among young people living with vertically acquired HIV receiving antiretroviral therapy: A qualitative analysis from the BREATHER Plus trial, South Africa. Global public health · 20 Aug 2026 PMID 42623024
  3. Risk of Virological Failure After Switch to a Tenofovir-Sparing Dual Therapy in Virologically Suppressed People With HIV and Past HBV Infection. Journal of medical virology · 21 Jul 2026 PMID 42479941
Observational studies and case reports (4)
  1. Burden and determinants of hyperglycaemia and dyslipidaemia in Zimbabwean adults living with HIV on dolutegravir-based first-line antiretroviral therapy: A cross-sectional study. PloS one · 7 Oct 2026 PMID 42842595
  2. Plasma dolutegravir exposure testing to identify people with HIV at highest risk for dolutegravir resistance (ITREMA-2): a two-centre, prospective implementation study in South Africa. The lancet. HIV · 2 Sept 2026 PMID 42685737
  3. ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir/lamivudine. Sexual health · 19 Aug 2026 PMID 42618052
  4. Low-Level Viremia and Spatial Heterogeneity Among Individuals on Dolutegravir-Based Antiretroviral Therapy in Botswana: A Nationwide Study (2016-2022). The Journal of infectious diseases · 17 Aug 2026 PMID 42605207
Human data, design not indexed (3)
  1. Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV. CPT: pharmacometrics & systems pharmacology · 30 Sept 2026 PMID 42811541
  2. Comparative metabolic safety of efavirenz-, dolutegravir-, and bictegravir-based antiretroviral regimens in HIV-infected adults: Evidence for weight-dependent lipid deterioration. Journal of infection and public health · 25 Jun 2026 PMID 42349058
  3. Use of Integrase Strand Transfer Inhibitors Among Children Living With HIV in Latin America and the Caribbean. The Pediatric infectious disease journal · 22 May 2026 PMID 42168824
Preclinical: animal, cell and lab studies (1)
  1. Nanoemulsion-based transdermal delivery of rilpivirine and dolutegravir for pediatric HIV treatment. International journal of pharmaceutics · 9 Jul 2026 PMID 42425238